A Phase 3 interventional study of Lurbinectedin (PM01183) and Doxorubicin (DOX) in Small-cell Lung Cancer, sponsored by PharmaMar. Completed at 160 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-28.
Sponsored by PharmaMar · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing PM 01183 in Small Cell Lung Carcinoma — 9 open to participants now, 11 under way, 3 of them phase 3. PM 01183 · Small Cell Lung Carcinoma.
Among the 16 studies testing PM 01183 in Small Cell Lung Carcinoma, this one is the 4th largest by enrollment, is the only one that started in 2016, is one of 5 in phase 3, and was the 2nd registered.
1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.
Browse Small Cell Lung Carcinoma studies →9 of the 16 studies testing PM 01183 in Small Cell Lung Carcinoma are open now, in 12 countries. Recruiting first, the newest first:
Misty Shields · Sites in United States
Ages 18+
Jazz Pharmaceuticals · Sites in United States
Ages 18+
Gilead Sciences · Sites in United States, Argentina, Australia and 20 more countries
Ages 18+
Luye Pharma Group Ltd. · Sites in China
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
By country, each count listing its studies:
PM 01183: first FDA approval 2020 (ZEPZELCA), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →
Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 5
First in 2013; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 613 is above the median of 56 across 1,077 interventional studies indexed under Small Cell Lung Carcinoma.
Median enrollment 69 across the 16 interventional studies. Of the 5 that completed or were terminated, 2 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 16 have an industry lead sponsor. The 10 most frequent:
PharmaMar is the lead sponsor of 50 studies on the registry; 5 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
PharmaMar has 3 studies filed under Small Cell Lung Carcinoma — fewer than ten, so there is no comparison to draw.
4 of the studies testing PM 01183 in Small Cell Lung Carcinoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06501976Cancer Institute and Hospital, Chinese Academy of Medical SciencesAn Exploratory Study of Lurbinectedin With Radiotherapy in SCLC With Single-lesion Progression After First Course Treatment | 2026-12 |
| NCT05578326UNC Lineberger Comprehensive Cancer CenterStudy of Trilaciclib and Lurbinectidin | 2026-12-25 |
| NCT07640932Yonsei UniversityLurbinectedin Plus Paclitaxel Versus Paclitaxel in Patients With Previously Treated Small Cell Lung Cancer | 2027-04 |
| NCT06228066National Cancer Institute (NCI)Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER) | 2027-09-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 16 studies testing PM 01183 in Small Cell Lung Carcinoma, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Phase III randomized clinical trial of lurbinectedin (PM01183)/doxorubicin (DOX) versus cyclophosphamide (CTX), doxorubicin (DOX) and vincristine (VCR) (CAV) or topotecan as treatment in patients with small-cell lung cancer (SCLC) who failed one prior platinum-containing line.
Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate and compare the activity and safety of an experimental arm consisting of PM01183/DOX combination followed by PM01183 alone, if applicable vs. best Investigator's choice between CAV or topotecan as a control arm, in SCLC patients who failed one prior platinum-containing line but no more than one prior chemotherapy-containing line.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Concomitant diseases/conditions:
Angina, myocardial infarction, congestive heart failure or valvular heart disease, arrhythmia, immunodeficiency (including known seropositive), ongoing or treatment-requiring chronic liver disease, active infection, oxygen requirement within two weeks prior to randomization, diffuse interstitial lung disease (ILD) or pulmonary fibrosis, second invasive treated with chemotherapy and/or radiotherapy, invasive fungal infections requiring systemic treatment within 12 weeks of randomization.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lurbinectedin (PM01183) / Doxorubicin
Drug: Lurbinectedin (PM01183) · Drug: Doxorubicin (DOX)
CAV (Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR))
Drug: Doxorubicin (DOX) · Drug: Cyclophosphamide (CTX) · Drug: Vincristine (VCR)
Topotecan
Drug: Topotecan
Overall Survival (OS)
Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).
Time frame: Every three months up to death or study termination, a period of approximately 3.5 years
Difference in Overall Survival Between Lurbinectedin/Doxorubicin (DOX) and CAV in Patients With CAV as Best Investigator's Choice: Overall Survival Rate at 12 Months
Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).
Time frame: At 12 months
Difference in Overall Survival Between Lurbinectedin/DOX and CAV in Patients With CAV as Best Investigator's Choice: Overall Survival Rate at 18 Months
Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).
Time frame: At 18 months
Difference in Overall Survival Between Lurbinectedin/DOX and CAV in Patients With CAV as Best Investigator's Choice: Overall Survival Rate at 24 Months
Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).
Time frame: At 24 months
Progression-free Survival (PFS) by Independent Review Committee
Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.
Time frame: Every six weeks up to progression disease, a period of approximately 3.5 years
Progression-free Survival Rate at 6 Months by Independent Review Committee
Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.
Time frame: At 6 months
Progression-free Survival Rate at 12 Months by Independent Review Committee
Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.
Time frame: at 12 months
Best Antitumor Response by Independent Review Committee
Best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown
Time frame: Every three months up to death or study termination, a period of approximately 3.5 years
Overall Response Rate by Independent Review Committee
Overall response rate is defined as the proportion of patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown
Time frame: Every three months up to death or study termination, a period of approximately 3.5 years
Duration of Response by Independent Review Committee
Duration of Response is defined as the time that patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown
Time frame: Every three months up to death or study termination, a period of approximately 3.5 years
Overall Survival in Patients With Chemotherapy-free Interval ≥ 90 Days
Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).
Time frame: Every three months up to death or study termination, a period of approximately 3.5 years
Progression-free Survival in Patients With Chemotherapy-free Interval ≥90 Days
Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.
Time frame: Every six weeks up to progression disease, a period of approximately 3.5 years
Best Antitumor Response in Patients With Chemotherapy-free Interval ≥ 90 Days
Best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown
Time frame: Every three months up to death or study termination, a period of approximately 3.5 years
Overall Response Rate in Patients With Chemotherapy-free Interval ≥ 90 Days
Overall response rate is defined as the proportion of patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown
Time frame: Every three months up to death or study termination, a period of approximately 3.5 years
Duration of Response in Patients With Chemotherapy-free Interval ≥ 90 Days
Duration of Response is defined as the time that patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown
Time frame: Every three months up to death or study termination, a period of approximately 3.5 years
Overall Survival in Patients With Chemotherapy-free Interval < 90 Days
Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).
Time frame: Every three months up to death or study termination, a period of approximately 3.5 years
Progression-free Survival in Patients With Chemotherapy-free Interval <90 Days
Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.
Time frame: Every six weeks up to progression disease, a period of approximately 3.5 years
Best Antitumor Response in Patients With Chemotherapy-free Interval <90 Days
Best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown
Time frame: Every three months up to death or study termination, a period of approximately 3.5 years
Overall Response Rate in Patients With Chemotherapy-free Interval <90 Days
Overall response rate is defined as the proportion of patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown
Time frame: Every three months up to death or study termination, a period of approximately 3.5 years
Duration of Response in Patients With Chemotherapy-free Interval <90 Days
Duration of Response is defined as the time that patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown
Time frame: Every three months up to death or study termination, a period of approximately 3.5 years
Overall Survival in Patients Without Central Nervous System Involvement at Baseline
Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).
Time frame: Every three months up to death or study termination, a period of approximately 3.5 years
Progression-free Survival in Patients Without Central Nervous System Involvement at Baseline
Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.
Time frame: Every six weeks up to progression disease, a period of approximately 3.5 years
Best Antitumor Response in Patients Without Central Nervous System Involvement at Baseline
Best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown
Time frame: Every three months up to death or study termination, a period of approximately 3.5 years
Overall Response Rate in Patients Without Central Nervous System Involvement at Baseline
Overall response rate is defined as the proportion of patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown
Time frame: Every three months up to death or study termination, a period of approximately 3.5 years
Duration of Response in Patients Without Central Nervous System Involvement at Baseline
Duration of Response is defined as the time that patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown
Time frame: Every three months up to death or study termination, a period of approximately 3.5 years
Overall Survival in Patients With Central Nervous System Involvement at Baseline
Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).
Time frame: Every three months up to death or study termination, a period of approximately 3.5 years
Progression-free Survival in Patients With Central Nervous System Involvement at Baseline
Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.
Time frame: Every six weeks up to progression disease, a period of approximately 3.5 years
Best Antitumor Response in Patients With Central Nervous System Involvement at Baseline
Best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown
Time frame: Every three months up to death or study termination, a period of approximately 3.5 years
Overall Response Rate in Patients With Central Nervous System Involvement at Baseline
Overall response rate is defined as the proportion of patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown
Time frame: Every three months up to death or study termination, a period of approximately 3.5 years
Duration of Response in Patients With Central Nervous System Involvement at Baseline
Duration of Response is defined as the time that patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown
Time frame: Every three months up to death or study termination, a period of approximately 3.5 years
The first randomization took place on 30 August 2016 and the first study treatment was administered on 25 October 2016. The cutoff date for results presented in this Clinical Study Report was 24 February 2020. A total of 919 patients were screened; 613 of these 919 patients were randomized at a 1:1 ratio to receive any of the study treatments at 135 investigational sites from 20 countries.
| Milestone | Lurbinectedin/Doxorubicin | Topotecan or Cyclophosphamide/Doxorubicin/Vincristine |
|---|---|---|
| Started | 307 | 306 |
| Completed | 0 | 0 |
| Not completed | 307 | 306 |
| Withdrew: Randomized but not treated | 5 | 16 |
| Withdrew: Progressive disease | 213 | 152 |
| Withdrew: Withdrawal by subject | 12 | 28 |
| Withdrew: Death | 17 | 23 |
| Withdrew: Physician decision | 10 | 17 |
| Withdrew: Study drug-related adverse event | 20 | 41 |
| Withdrew: Non study drug-related adverse event | 9 | 9 |
| Withdrew: Symptomatic deterioration | 9 | 16 |
| Withdrew: End of study due to events required for os analysis according to study protocol had been reached | 9 | 1 |
| Withdrew: Sponsor's decision after incorrect treatment at site | 1 | 1 |
| Withdrew: Screening failure | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Symptomatic deterioration, progression disease, and a decision by the investigator | 0 | 1 |
Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).
| months | Lurbinectedin/Doxorubicin | Topotecan or Cyclophosphamide/Doxorubicin/Vincristine |
|---|---|---|
| Overall Survival (OS) | 8.6 (7.1 to 9.4) | 7.6 (6.6 to 8.2) |
Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).
| percentage of participants | Lurbinectedin/Doxorubicin | Topotecan or Cyclophosphamide/Doxorubicin/Vincristine |
|---|---|---|
| Difference in Overall Survival Between Lurbinectedin/Doxorubicin (DOX) and CAV in Patients With CAV as Best Investigator's Choice: Overall Survival Rate at 12 Months | 29.6 (22.8 to 36.3) | 24.4 (17.9 to 31.0) |
Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).
| percentage of participants | Lurbinectedin/Doxorubicin | Topotecan or Cyclophosphamide/Doxorubicin/Vincristine |
|---|---|---|
| Difference in Overall Survival Between Lurbinectedin/DOX and CAV in Patients With CAV as Best Investigator's Choice: Overall Survival Rate at 18 Months | 13.9 (8.8 to 19.1) | 15.9 (10.3 to 21.4) |
Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).
| percentage of participants | Lurbinectedin/Doxorubicin | Topotecan or Cyclophosphamide/Doxorubicin/Vincristine |
|---|---|---|
| Difference in Overall Survival Between Lurbinectedin/DOX and CAV in Patients With CAV as Best Investigator's Choice: Overall Survival Rate at 24 Months | 8.6 (4.1 to 13.1) | 8.7 (4.1 to 13.4) |
Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.
| months | Lurbinectedin/Doxorubicin | Topotecan or Cyclophosphamide/Doxorubicin/Vincristine |
|---|---|---|
| Progression-free Survival (PFS) by Independent Review Committee | 4.0 (2.8 to 4.2) | 4.0 (3.0 to 4.1) |
Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.
| percentage of participants | Lurbinectedin/Doxorubicin | Topotecan or Cyclophosphamide/Doxorubicin/Vincristine |
|---|---|---|
| Progression-free Survival Rate at 6 Months by Independent Review Committee | 31.3 (25.7 to 36.8) | 24.4 (18.9 to 29.9) |
Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.
| percentage of participants | Lurbinectedin/Doxorubicin | Topotecan or Cyclophosphamide/Doxorubicin/Vincristine |
|---|---|---|
| Progression-free Survival Rate at 12 Months by Independent Review Committee | 10.8 (6.7 to 14.9) | 4.4 (1.4 to 7.4) |
Best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown
| Participants | Lurbinectedin/Doxorubicin | Topotecan or Cyclophosphamide/Doxorubicin/Vincristine |
|---|---|---|
| Complete response | 8 | 4 |
| Partial response | 89 | 87 |
| Stable disease | 111 | 116 |
| Progressive disease | 74 | 52 |
| Unknown | 25 | 47 |
Overall response rate is defined as the proportion of patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown
| percentage of participants | Lurbinectedin/Doxorubicin | Topotecan or Cyclophosphamide/Doxorubicin/Vincristine |
|---|---|---|
| Overall Response Rate by Independent Review Committee | 31.6 (26.4 to 37.1) | 29.7 (24.7 to 35.2) |
Duration of Response is defined as the time that patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown
| months | Lurbinectedin/Doxorubicin | Topotecan or Cyclophosphamide/Doxorubicin/Vincristine |
|---|---|---|
| Duration of Response by Independent Review Committee | 5.7 (4.1 to 7.1) | 3.8 (2.8 to 4.3) |
Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).
| months | Lurbinectedin/Doxorubicin | Topotecan or Cyclophosphamide/Doxorubicin/Vincristine |
|---|---|---|
| Overall Survival in Patients With Chemotherapy-free Interval ≥ 90 Days | 10.3 (9.0 to 11.8) | 8.7 (7.8 to 9.8) |
Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.
| months | Lurbinectedin/Doxorubicin | Topotecan or Cyclophosphamide/Doxorubicin/Vincristine |
|---|---|---|
| Progression-free Survival in Patients With Chemotherapy-free Interval ≥90 Days | 4.8 (4.1 to 5.6) | 4.4 (4.0 to 5.3) |
Best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown
| Participants | Lurbinectedin/Doxorubicin | Topotecan or Cyclophosphamide/Doxorubicin/Vincristine |
|---|---|---|
| Complete response | 8 | 4 |
| Partial response | 69 | 68 |
| Stable disease | 85 | 73 |
| Progression disease | 32 | 35 |
| Unknown | 14 | 25 |
Overall response rate is defined as the proportion of patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown
| percentage of participants | Lurbinectedin/Doxorubicin | Topotecan or Cyclophosphamide/Doxorubicin/Vincristine |
|---|---|---|
| Overall Response Rate in Patients With Chemotherapy-free Interval ≥ 90 Days | 37.0 (30.4 to 44.0) | 35.1 (28.6 to 42.1) |
Duration of Response is defined as the time that patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown
| months | Lurbinectedin/Doxorubicin | Topotecan or Cyclophosphamide/Doxorubicin/Vincristine |
|---|---|---|
| Duration of Response in Patients With Chemotherapy-free Interval ≥ 90 Days | 6.9 (4.1 to 8.3) | 4.0 (3.0 to 4.8) |
Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).
| months | Lurbinectedin/Doxorubicin | Topotecan or Cyclophosphamide/Doxorubicin/Vincristine |
|---|---|---|
| Overall Survival in Patients With Chemotherapy-free Interval < 90 Days | 5.7 (4.1 to 6.7) | 5.3 (4.2 to 6.1) |
Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.
| months | Lurbinectedin/Doxorubicin | Topotecan or Cyclophosphamide/Doxorubicin/Vincristine |
|---|---|---|
| Progression-free Survival in Patients With Chemotherapy-free Interval <90 Days | 1.6 (1.4 to 2.7) | 2.8 (2.5 to 3.0) |
Best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown
| Participants | Lurbinectedin/Doxorubicin | Topotecan or Cyclophosphamide/Doxorubicin/Vincristine |
|---|---|---|
| Partial response | 20 | 19 |
| Stable disease | 26 | 43 |
| Progression disease | 42 | 17 |
| Unknown | 11 | 22 |
Overall response rate is defined as the proportion of patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown
| percentage of participants | Lurbinectedin/Doxorubicin | Topotecan or Cyclophosphamide/Doxorubicin/Vincristine |
|---|---|---|
| Overall Response Rate in Patients With Chemotherapy-free Interval <90 Days | 20.2 (12.8 to 29.5) | 18.8 (11.7 to 27.8) |
Duration of Response is defined as the time that patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown
| months | Lurbinectedin/Doxorubicin | Topotecan or Cyclophosphamide/Doxorubicin/Vincristine |
|---|---|---|
| Duration of Response in Patients With Chemotherapy-free Interval <90 Days | 3.0 (1.4 to 4.5) | 2.8 (1.4 to 4.1) |
Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).
| months | Lurbinectedin/Doxorubicin | Topotecan or Cyclophosphamide/Doxorubicin/Vincristine |
|---|---|---|
| Overall Survival in Patients Without Central Nervous System Involvement at Baseline | 9.1 (8.1 to 10.2) | 7.7 (6.7 to 8.6) |
Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.
| months | Lurbinectedin/Doxorubicin | Topotecan or Cyclophosphamide/Doxorubicin/Vincristine |
|---|---|---|
| Progression-free Survival in Patients Without Central Nervous System Involvement at Baseline | 4.2 (3.7 to 4.8) | 4.1 (3.1 to 4.3) |
Best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown
| Participants | Lurbinectedin/Doxorubicin | Topotecan or Cyclophosphamide/Doxorubicin/Vincristine |
|---|---|---|
| Complete response | 7 | 3 |
| Partial response | 79 | 76 |
| Stable disease | 101 | 100 |
| Progression disease | 55 | 40 |
| Unknown | 19 | 38 |
Overall response rate is defined as the proportion of patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown
| percentage of participants | Lurbinectedin/Doxorubicin | Topotecan or Cyclophosphamide/Doxorubicin/Vincristine |
|---|---|---|
| Overall Response Rate in Patients Without Central Nervous System Involvement at Baseline | 33.0 (27.3 to 39.0) | 30.7 (25.2 to 36.8) |
Duration of Response is defined as the time that patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown
| months | Lurbinectedin/Doxorubicin | Topotecan or Cyclophosphamide/Doxorubicin/Vincristine |
|---|---|---|
| Duration of Response in Patients Without Central Nervous System Involvement at Baseline | 5.7 (4.1 to 7.3) | 4.0 (3.0 to 4.9) |
Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).
| months | Lurbinectedin/Doxorubicin | Topotecan or Cyclophosphamide/Doxorubicin/Vincristine |
|---|---|---|
| Overall Survival in Patients With Central Nervous System Involvement at Baseline | 4.6 (3.1 to 6.1) | 6.6 (4.0 to 8.8) |
Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.
| months | Lurbinectedin/Doxorubicin | Topotecan or Cyclophosphamide/Doxorubicin/Vincristine |
|---|---|---|
| Progression-free Survival in Patients With Central Nervous System Involvement at Baseline | 1.9 (1.4 to 2.7) | 2.8 (1.4 to 3.8) |
Best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown
| Participants | Lurbinectedin/Doxorubicin | Topotecan or Cyclophosphamide/Doxorubicin/Vincristine |
|---|---|---|
| Complete response | 1 | 1 |
| Partial response | 10 | 11 |
| Stable disease | 10 | 16 |
| Progression disease | 19 | 12 |
| Unknown | 6 | 9 |
Overall response rate is defined as the proportion of patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown
| percentage of participants | Lurbinectedin/Doxorubicin | Topotecan or Cyclophosphamide/Doxorubicin/Vincristine |
|---|---|---|
| Overall Response Rate in Patients With Central Nervous System Involvement at Baseline | 23.9 (12.6 to 38.8) | 24.5 (13.3 to 38.9) |
Duration of Response is defined as the time that patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown
| months | Lurbinectedin/Doxorubicin | Topotecan or Cyclophosphamide/Doxorubicin/Vincristine |
|---|---|---|
| Duration of Response in Patients With Central Nervous System Involvement at Baseline | 1.5 (0.1 to NA) | 2.7 (1.3 to 4.0) |
Collected over Patients were assessed through study completion, approximately 2 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lurbinectedin/Doxorubicin | 264/303 (87.1%) | 126/303 (41.6%) | 292/303 (96.4%) |
| Topotecan | 100/121 (82.6%) | 66/121 (54.5%) | 120/121 (99.2%) |
| Cyclophosphamide/Doxorubicin/Vincristine | 148/168 (88.1%) | 75/168 (44.6%) | 148/168 (88.1%) |
| Event | Lurbinectedin/Doxorubicin | Topotecan | Cyclophosphamide/Doxorubicin/Vincristine |
|---|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 9/303 | 15/121 | 4/168 |
| AnaemiaBlood and lymphatic system disorders | 10/303 | 13/121 | 9/168 |
| Febrile neutropeniaBlood and lymphatic system disorders | 12/303 | 7/121 | 17/168 |
| NeutropeniaBlood and lymphatic system disorders | 4/303 | 9/121 | 12/168 |
| PneumoniaInfections and infestations | 14/303 | 5/121 | 7/168 |
| FatigueGeneral disorders | 4/303 | 5/121 | 2/168 |
| Lower respiratory tract infectionInfections and infestations | 5/303 | 5/121 | 6/168 |
| General physical health deteriorationGeneral disorders | 7/303 | 4/121 | 5/168 |
| SepsisInfections and infestations | 3/303 | 4/121 | 2/168 |
| Septic shockInfections and infestations | 0/303 | 4/121 | 4/168 |
| Event | Lurbinectedin/Doxorubicin | Topotecan | Cyclophosphamide/Doxorubicin/Vincristine |
|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 121/303 | 84/121 | 89/168 |
| NeutropeniaBlood and lymphatic system disorders | 101/303 | 74/121 | 107/168 |
| ThrombocytopeniaBlood and lymphatic system disorders | 70/303 | 71/121 | 61/168 |
| FatigueGeneral disorders | 164/303 | 64/121 | 79/168 |
| NauseaGastrointestinal disorders | 123/303 | 33/121 | 55/168 |
| Decreased appetiteMetabolism and nutrition disorders | 85/303 | 20/121 | 40/168 |
| LeukopeniaBlood and lymphatic system disorders | 28/303 | 32/121 | 46/168 |
| ConstipationGastrointestinal disorders | 59/303 | 30/121 | 25/168 |
| VomitingGastrointestinal disorders | 72/303 | 15/121 | 33/168 |
| Weight decreasedInvestigations | 64/303 | 14/121 | 24/168 |
| Age, Continuous(years) | Lurbinectedin/Doxorubicin | Topotecan or Cyclophosphamide/Doxorubicin/Vincristine | Total |
|---|---|---|---|
| Median | 63.0 (19 to 83) | 63.0 (37 to 82) | 63 (19 to 83) |
| Age, Customized(Participants) | Lurbinectedin/Doxorubicin | Topotecan or Cyclophosphamide/Doxorubicin/Vincristine | Total |
|---|---|---|---|
| 18-49 years | 16 | 13 | 29 |
| 50-65 years | 161 | 166 | 327 |
| >65 years | 130 | 127 | 257 |
| Sex: Female, Male(Participants) | Lurbinectedin/Doxorubicin | Topotecan or Cyclophosphamide/Doxorubicin/Vincristine | Total |
|---|---|---|---|
| Female | 131 | 133 | 264 |
| Male | 176 | 173 | 349 |
| Race/Ethnicity, Customized(Participants) | Lurbinectedin/Doxorubicin | Topotecan or Cyclophosphamide/Doxorubicin/Vincristine | Total |
|---|---|---|---|
| White | 266 | 265 | 531 |
| Black or African American | 1 | 1 | 2 |
| Asian | 0 | 1 | 1 |
| Other | 2 | 2 | 4 |
| Not available | 38 | 37 | 75 |
| Region of Enrollment(Participants) | Lurbinectedin/Doxorubicin | Topotecan or Cyclophosphamide/Doxorubicin/Vincristine | Total |
|---|---|---|---|
| Argentina | 3 | 4 | 7 |
| Romania | 20 | 19 | 39 |
| Hungary | 23 | 23 | 46 |
| United States | 32 | 30 | 62 |
| Czechia | 4 | 5 | 9 |
| United Kingdom | 10 | 11 | 21 |
| Portugal | 10 | 5 | 15 |
| Spain | 62 | 63 | 125 |
| Greece | 12 | 13 | 25 |
| Lebanon | 8 | 9 | 17 |
| Canada | 10 | 7 | 17 |
| Austria | 5 | 3 | 8 |
| Netherlands | 9 | 9 | 18 |
| Belgium | 9 | 12 | 21 |
| Brazil | 13 | 15 | 28 |
| Poland | 7 | 6 | 13 |
| Italy | 21 | 20 | 41 |
| Bulgaria | 5 | 6 | 11 |
| France | 11 | 12 | 23 |
| Germany | 33 | 34 | 67 |
| Weight(Kg) | Lurbinectedin/Doxorubicin | Topotecan or Cyclophosphamide/Doxorubicin/Vincristine | Total |
|---|---|---|---|
| Median | 73.0 (40 to 143) | 74.0 (38 to 158) | 73.4 (37.9 to 158) |
| Height(cm) | Lurbinectedin/Doxorubicin | Topotecan or Cyclophosphamide/Doxorubicin/Vincristine | Total |
|---|---|---|---|
| Median | 168 (145 to 196) | 168 (146 to 191) | 168 (145 to 196) |
| Body surface area(m^2) | Lurbinectedin/Doxorubicin | Topotecan or Cyclophosphamide/Doxorubicin/Vincristine | Total |
|---|---|---|---|
| Median | 1.8 (1.4 to 2.5) | 1.8 (1.3 to 2.8) | 1.8 (1.3 to 2.8) |
20 further baseline measures are reported on the registry.
Showing the first 100 of 160 sites across 20 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2016 to primary completion in Feb 2020, 41 months.
Results were first posted in Oct 2021, 1 year 8 months after primary completion.
Of 55 industry-sponsored phase 3 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 44. This study's 41 months is above that.
Counting every sponsor, half of 68 studies reached it within 41 months; a quarter within 31 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: PM 01183 · Doxorubicin